SREBF1 and metabolic dysfunction-associated steatohepatitis: As previously reported in human livers27, 28, 29, 30, 31, 32, 33, SREBP1c expression was significantly decreased in NAFL patients compared to control whereas it was increased in NASH patients compared to NAFL2 (Supplemental Fig. S5f).